longer subject to

Section 16. Form 4 or

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

OMB APPROVAL OMB 3235-Number: 0287 Estimated average burden hours per response...

11. Nature

Form 5 obligations may continue. *See* Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Typ	pe Response	es)							_					
Name and Address of Reporting Person = Saks Samuel R				2. Issuer Name and Ticker or Trading Symbol Tonix Pharmaceuticals Holding Corp. [TNXP]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
(Last) (First) (Middle) C/O TONIX PHARMACEUTICALS HOLDING CORP., 509 MADISON AVENUE, SUITE 306				3. Date of Earliest Transaction (Month/Day/Year) 02/25/2015					below)					
(Street) NEW YORK, NY 10022				4. If Amendment, Date Original Filed(Month/Day/Year)					6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(Sta	te) (Zip)		Table I -	Non-	Derivativ	e Securities	Acqu	ired, Disposed of, or	Beneficially	Owned			
1.Title of Se (Instr. 3)	Da (N	ate Month/Day/Year)	Execu any (Mon	ution Date, if nth/Day/Year)	Code (Instr	saction A D r. 8) (I))	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Benefi Owner	rect cial ship		
Reminder: R directly or ir		separate line for ea	ich cla	ass of securitie	s ben	eficially o	wned							
						info requ	rmation co uired to res	ntain pond	nd to the collection ed in this form are I unless the form d I control number.	not	SEC (9	1474 1-02)		
		Table II - I	eriva	ative Securitie	s Acc	quired, D	isposed of, o	r Ber	neficially Owned					
		(6	.g., p	uts, calls, wa	rrant	s, options	s, convertibl	e secu	rities)					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of	3. Transaction Date (Month/Day/Ye	ear) a	A. Deemed Execution Date ny Month/Day/Ye	(Transaction Code		Exp	nth/Day/Year)	7. Title and A of Underlyin Securities (Instr. 3 and	g	Derivative Security	 Number of Derivative Securities Beneficially 	10. Ow For De

Derivative	Conversion	Date	Execution Date, if	Transaction o		of		Expiration Date		of Underlying		Derivative	Derivative	Ownership	of Indirect
Security	or Exercise	(Month/Day/Year)	any	Code		Deriva	tive	(Month/Day	/Year)	Securities		Security	Securities	Form of	Beneficial
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)		Securities				(Instr. 3 and 4)		(Instr. 5)	Beneficially	Derivative	Ownership
	Derivative			Acquired							Owned	Security:	(Instr. 4)		
	Security					(A) or							Following	Direct (D)	i
						Dispos	osed						Reported	or Indirect	i
						of (D)							Transaction(s)	(I)	i
						(Instr.	3, 4,						(Instr. 4)	(Instr. 4)	
						and 5)									i
											Amount				i
								ъ.	E :		or				i
									Expiration	Title	Number				
								Exercisable	Date		of				ĺ
				Code	V	(A)	(D)				Shares				
Stock Option	\$ 5.95	02/25/2015		A		5,000		<u>(1)</u>	02/25/2025	Common Stock	5,000	\$0 ⁽²⁾	5,000	D	
Restricted Stock	(<u>3)</u>	02/25/2015		A		6,000		<u>(4)</u>	<u>(4)</u>	Common	6,000	\$ 0 <u>(5)</u>	6,000	D	

Stock

Reporting Owners

Depositing Owner Name / Address	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Saks Samuel R C/O TONIX PHARMACEUTICALS HOLDING CORP. 509 MADISON AVENUE, SUITE 306 NEW YORK, NY 10022	X						

Signatures

Unit

/s/Jessica Edgar, Attorney-in-Fact	02/27/2015			
Signature of Reporting Person	Date			

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The option vests 1/3rd on the first anniversary of issuance and 1/36th each month thereafter for 24 months.
- (2) The option was granted pursuant to the Issuer's 2014 Stock Incentive Plan.
- (3) Each restricted stock unit represents the right to receive, at settlement, one share of common stock.
- (4) These restricted stock units are scheduled to vest 100% on February 25, 2016.
- (5) The restricted stock units were granted pursuant to the Issuer's 2014 Stock Incentive Plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.